Fox19: 'Chemobrain' and music
UC DAAP expert discusses collaborative project using a music app to address chemobrain in patients
Claudia Rebola, PhD, associate dean for research and associate professor in industrial design for DAAP. “I am always fascinated by ways to embrace the creative disciplines to help people and improve their well-being and quality of life through the use of design," she says. Photo/UC Creative + Brand
Music as medicine has become a more widely adopted concept. Now, UC experts at the College of Design, Architecture, Art and Planning are working with colleagues at the UC Gardner Neuroscience Institute and the UC Cancer Center to blend music with recovery for patients who have undergone chemotherapy as part of treatment.
This collaborative project — a music app — evolved from the ideas of experts at the UC College of Medicine who wanted to help patients and survivors experiencing "chemobrain".
Claudia Rebola, PhD, associate dean for research and associate professor in industrial design for DAAP, spoke to Fox19 about the creation of the app.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.